Cingulate Inc. (CING)

1.1200 +0.0800 (+7.69%) 收市：04:00PM EDT

Cingulate Inc.

1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com

版塊: Healthcare
行業: Biotechnology
全職員工: 13

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Shane J. Schaffer Pharm.D., PharmD	CEO & Chairman of the Board	491.96k	無	1975
Dr. Laurie A. Myers M.B.A., Ph.D.	Executive VP & COO	415.17k	無	1957
Dr. Matthew N. Brams M.D.	Executive VP & Chief Medical Officer	244.79k	無	1964
Dr. Raul R. Silva M.D.	Executive VP & Chief Science Officer	無	無	1958
Thomas Dalton	Vice President of Investor & Public Relations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

公司管治

截至 無 止，Cingulate Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。